Annexon Biosciences

2 followers

‌

Annexon is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain, and eye.

Industries

Biotechnology, Health & Wellness

Headquarters

South San Francisco, United States

Employees

51-200

Links

Org chart

Douglas Love

President & Chief Executive Officer

Douglas Love

Collapse

Michael Overdorf

EVP & Chief Business Officer

Rick Artis

Chief Scientific Officer

Jennifer Lew

EVP & Chief Financial Officer

Ted Yednock

EVP & Chief Innovation Officer

Dean Richard Artis

EVP And Chief Scientific Officer

Jamie Dananberg

EVP & Chief Medical Officer

AJ Acker

Senior Vice President, Regulatory, Quality & Clinical Safety

Behn Sarafpour

Vice President Medical Affairs

Cecilia Oliyai

Senior Vice President CMC Operations

John Hanna

VP & Head of Clinical Safety

Peter Collins

Vp, Global Program Team Lead - Neurodegeneration Franchise

Henk-Andre Kroon

Svp, Head Of Translational Medicine

Kunal Kanani

Vice President Regulatory Affairs

Ping Lin

Senior Director, Head Of Biostatistics

Ranjith K.

Director, Head Of Statistical Programming

Teams

+16

Clinical Development and Operations

19 members

Leadership Team

4 members

Similar companies

Summit Therapeutics

4 followers

4D Molecular Therapeutics

3 followers

Pivot Bio

2 followers

Frontier Health

14 followers

Bardavon Health Innovations

1 follower

Evolus

1 follower

Matica Biotechnology

1 follower

Nutrafol

7 followers

CVS Health

375 followers

Thermo Fisher Scientific

165 followers

Cigna

146 followers

Explore companies